Transient ischemia inhibits nonexocytotic release of norepinephrine following sustained ischemia in rat heart: Is bradykinin involved?

Canadian Journal of Physiology and Pharmacology

Volumn 75, Issue 6, 1997, Pages 665-670

  Feng, Jun ^a   Yamaguchi, Nobuharu ^a   Foucart, Sylvain ^a   Chahine, Ramez ^a   Lamontagne, Daniel ^a   Nadeau, Réginald ^a  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Bradykinin; Cardiac ischemia; Kinin receptors; Norepinephrine release; Preconditioning

Indexed keywords

BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ DERIVATIVE; BRADYKININ[1-8]; ICATIBANT;

ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; HEART MUSCLE ISCHEMIA; IN VITRO STUDY; MALE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; REPERFUSION;

EID: 0030690201     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y97-072     Document Type: Conference Paper

References (49)

1. Ardell, J.L., Yang, X.M., Barron, B.A., Downey, J.M., and Cohen, A.M. 1996. Endogenous myocardial norepinephrine is not essential for ischemic preconditioning in rabbit heart. Am. J. Physiol. 270:H1078-H1084.
2. Banerjee, A., Locke-Winter, C., Rogers, K.B., Mitchell, M., Btew, E., Cairns, C., Bensard, D., and Harken, A. 1993. Preconditioning against myocardial dysfunction after ischemia and reperfusion by an α1-adrenergic mechanism. Circ. Res. 73: 656-670.
3. Baumgarten, C.R., Linz, W., Kunkel, G., Scholkens, B.A., and Wiemer, G. 1993. Ramiprilat increases bradykinin outflow from isolated rat hearts. Br. J. Pharmacol. 108: 293-295.
4. Brew, E.C., Mitchell, M.B., Rehring, T.F., Gamboni-Robertson, F., McIntyre, R.C. Jr., Harken, A.H., and Banerjee, A. 1995. Role of bradykinin in cardiac functional protection after global ischemia-reperfusion in rat heart. Am. J. Physiol. 269: H1370-H1378.
5. Bugge, E., and Ytrehus, K. 1995. Bradykinin can protect against infarction but does not mediate ischemic preconditioning in the rat heart. Circulation, 92(Suppl. I): 1-456. (Abstr.)
6. Carlsson, L., and Abrahamsson, T. 1989. Ramiprilat attenuates the local release of noradrenaline in the ischemic myocardium. Eur. J. Pharmacol. 166: 157-164.
7. Cave, A.C., and Hearse, D.J. 1992. Ischemic preconditioning enhances post-ischemic function and reduces creatine kinase leakage in the rat heart even when used in conjunction with hypothermic cardioplegia. Circulation, 86(Suppl. I): 31. (Abstr.)
8. 1 receptors. Br. J. Pharmacol. 108: 318-322.
9. Chahine, R.A., Nadeau, R., Lamontagne, D., Yamaguchi, N., and de Champlain, J. 1994. Norepinephrine and dihydroxyphenylglycol effluxes from sympathetic nerve endings during hypoxia and reoxygenation in the isolated rat heart. Can. J. Physiol. Pharmacol. 72: 595-601.
10. Cohen, M.V., Lui, G.S., and Downey, J.M. 1991. Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary occlusion in rabbits. Circulation, 84: 341-349.
11. de Jong, J.W., Cargnoni, A., Bradamante, S., Curello, S., Janssen, J., Pasini, E., and Ceconi, E. 1995. Intermittent V continuous ischaemia decelerates adenylate breakdown and prevents norepinephrine release in reperfused rabbit heart. J. Mol. Cell. Cardiol. 27: 659-671.
12. Feng, J., Yamaguchi, N., Lamontagne, N., Chahine, R., and Nadeau, R. 1994. Perfusate potassium: effect on ischemia and reperfusion arrhythmias in ischemic preconditioning in the isolated rat heart. J. Mol. Cell. Cardiol. 26: A144. (Abstr.)
13. Feng, J., Atanasiu, R., Yamaguchi, N., Lamontagne, N., Chahine, R., and Nadeau, R. 1995a. Effects of ischemic preconditioning and hypothermia on ischemic contracture in isolated rat heart. Med. Sci. Res. 23: 787-788.
14. Feng, J., Chahine, R., Yamaguchi, N., Lamontagne, D., and Nadeau, R. 1995b. Brief repetitive ischemia: effect on norepinephrine release, functional recovery and arrhythmias in isolated perfused rat hearts. J. Mol. Cell. Cardiol. 27: A48. (Abstr.).
15. Finegan, B.A., Lopaschuk, G.D., Gandhi, M., and Clanachan, A.S. 1995. Ischemic preconditioning inhibits glycolysis and proton production in isolated working rat hearts. Am. J. Physiol. 269: H1767-H1775.
16. Godin, D., Campeau, N., Nadeau, R., Cardinal, R., and de Champlain, J. 1985. Catecholamine release and ventricular arrhythmias during coronary occlusion and reperfusion in the dog. Can. J. Physiol. Pharmacol. 63: 1088-1095.
17. Goto, M., Liu, Y., Yang, X.M., Ardell, J.L., Cohen, M.V., and Downey, J.M. 1995. Role of bradykinin in protection of ischemic preconditioning in rabbits. Circ. Res. 77: 611-621.
18. Hall, J.M. 1992. Bradykinin receptors: pharmacological properties and biological roles. Pharmacol. Ther. 56: 131-190.
19. Hess, J.F., Borkowski, J.A., Stonesifer, G.Y., Young, G.S., Strader, C.D., and Ransom, R.W. 1992. Cloning and pharmacological characterization of human bradykinin (BK-2) receptors. Biochem. Biophys. Res. Commun. 45: 1-8.
20. Hock, F.J., Wirth, K., Albus, U., Linz, W., Gerhards, H.J., Wiemer, G., Henke, S., Breipohl, G., Konig, W., Knolle, J., and Scholkens, B.A. 1991. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br. J. Pharmacol. 102: 769-773.
21. Lamontagne, D., Yamaguchi, N., Nadeau, R., de Champlain, J., Godin, D., and Campeau, N. 1986. Effects of sotalol, l-propranolol and prazosin on reperfusion-induced arrhythmias and increased norepinephrine release. Eur. J. Pharmacol. 123: 1-10.
22. 9-bradykinin release following reperfusion of the ischemic rat heart. Br. J. Pharmacol. 115: 476-478.
23. Lawson, C.S., and Downey, J.M. 1993. Preconditioning: state of the art of myocardial protection. Cardiovasc. Res. 27: 542-550.
24. Li, Y.W., Whittaker, P., and Kloner, R.A. 1992. The transient nature of the effect of ischemic preconditioning on myocardial infarct size and ventricular arrhythmia. Am. Heart J. 123: 346-353.
25. Linz, W., and Scholkens, B.A. 1987. Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts. J. Cardiovasc. Pharmacol. 10(Suppl. VII): S75-S82.
26. Linz, W., and Scholkens, B.A. 1992. Role of bradykinin in the cardiac effects of angiotensin-converting enzyme inhibitors. J. Cardiovasc. Pharmacol. 20(Suppl. 9): S83-S99.
27. 1 receptors: a review. Immunopharmacology, 30: 1-26.
28. Martorana, P.A., Kettenbach, B., Breipohl, G., Linz, W., and Scholkens, B.A. 1990. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur. J. Pharmacol. 182: 395-396.
29. 1 bradykinin receptor. J. Biol. Chem. 269: 21 583-21 586.
30. Murry, C.E., Jennings, R.B., and Reimer, K.A. 1986. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation, 74: 1124-1136.
31. Nadeau, R., and de Champlain, J. 1979. Plasma catecholamines in acute myocardial infarction. Am. Heart J. 98: 548-554.
32. Regoli, D., and Barabé, J. 1980. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 32: 1-46.
33. Ribuot, C., Yamaguchi, N., Godin, D., Jetté, L., Adam, A., and Nadeau, R. 1994. Intracoronary infusion of bradykinin: effects on noradrenaline overflow following reperfusion of ischemic myocardium in the anesthetized dog. Fundam. Clin. Pharmacol. 8: 532-538.
34. Schömig, A. 1990. Catecholamines in myocardial ischemia. Systemic and cardiac release. Circulation, 82(Suppl. II): 13-22.
35. Schömig, A., Kurz, T., Richardt, G., and Schömig, E. 1988. Neuronal sodium homeostasis and axoplasmic amine concentration determine calcium-independent noradrenaline release in normoxic and ischemic rat heart.. Circ. Res. 63: 214-226.
36. Schott, R.J., Rohmann, S., Braun, E.R., and Schaper, W. 1990. Ischemic preconditioning reduces infarct size in swine myocardium. Circ. Res. 66: 1133-1142.
37. Seyfarth, M., Richardt, G., Mizsnyak, A., Kurz, T., and Schömig, A. 1996. Transient ischemia reduces norepinephrine release during sustained ischemia: neural preconditioning in isolated rat heart. Circ. Res. 78: 573-580.
38. Shiki, K., and Hearse, D.J. 1987. Preconditioning of ischemic myocardium: reperfusion-induced arrhythmias. Am. J. Physiol. 253: H1470-H1476.
39. Starkopf, J., and Ytrehus, K. 1995. Bradykinin and ischemic preconditioning in functional protection of the isolated rat heart. J. Mol. Cell. Cardiol. 7: A160. (Abstr.)
40. Steenbergen, C., Perlman, M.E., London, R.E., and Murphy, E. 1993. Mechanism of preconditioning ionic alteration. Circ. Res. 72: 112-125.
41. Tio, R.A., Tobe, T.J.M., Bel, K.J., de Langen, C.D.J., van Gilst, W.H., and Wesseling, H. 1991. Beneficial effects of bradykinin on porcine ischemic myocardium. Basic Res. Cardiol. 86: 107-116.
42. Tobe, T.J.M., de Langen, C.D.J., Tio, R.A., Bel, K.J., Mook, P.H., and Wesseling, H, 1991. In vivo effect of bradykinin during ischemia and reperfusion: improved electrical stability two weeks after myocardial infarction in the pig. J. Cardiovasc. Pharmacol. 17: 600-607.
43. Toombs, C.F., Wiltse, A.L., and Shebuski, RJ. 1993. Ischemic preconditioning fails to limit infarct size in reserpinized rabbit myocardium. Circulation, 88: 2351-2358.
44. 2 receptors. Br. J. Pharmacol. 113: 1167-1172.
45. Wall, T.M., Sheehy, R., and Hartman, J.C. 1994. Role of bradykinin in myocardial preconditioning. J. Pharmacol. Exp. Ther. 270: 681-689.
46. Weselcouch, E.D., Baird, A.J., Sleph, P.G., Dzwonczyk, S., and Murray, H.N. 1995. Endogenous catecholamines are not necessary for ischemic preconditioning in the isolated perfused rat heart. Cardiovasc. Res. 29: 126-132.
47. Yamaguchi, N., Kimura, T., Lamontagne, D., de Champlain, J., and Nadeau, R. 1990. Occlusion time dependency of regional noradrenaline release and cardiac arrhythmias during reperfusion of acutely ischaemic heart in the dog in vivo. Cardiovasc. Res. 24: 688-698.
48. Yellon, D.M., Alkhulaifi, A.M., and Pugsley, W.B. 1993. Preconditioning the human myocardium. Lancet, 342: 276-277.
49. Zhu, P., Zaugg, C.E., Simper, D., Hornstein, P., Allegrini, P.R., and Buser, P.T. 1995. Bradykinin improves postischemic recovery in the rat heart: role of high energy phosphates, nitric oxide, and prostacyclin. Cardiovasc. Res. 29: 658-663.